A Modified Carbapenem Inactivation Method, CIMTris, for Carbapenemase Production in Acinetobacter and Pseudomonas Species

Uechi, Kohei; Tada, Tatsuya; Shimada, Kayo; Kuwahara‐Arai, Kyoko; Arakaki, Momoko; Tome, Takaaki; Nakasone, Isamu; Maeda, Shiro; Kirikae, Teruo; Fujita, Jiro

doi:10.1128/jcm.00893-17

Cited by 45 publications

(30 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cross-transmission of bla GES-5 will be caused by the clonal nature of the outbreaks in medical settings in Japan. Microbiological laboratories therefore require methods to easily detect GES-5 producers, such as the Blue Carba test [ 26 , 27 ], the CIMTris [ 28 ] and a systematic bla GES PCR method.…”

Section: Discussionmentioning

confidence: 99%

Spread of GES-5 carbapenemase-producing Pseudomonas aeruginosa clinical isolates in Japan due to clonal expansion of ST235

et al. 2018

Self Cite

View full text Add to dashboard Cite

The first outbreak in Japan of GES-5 carbapenemase-producing Pseudomonas aeruginosa occurred in a long-term care facility in 2014. To assess the spread of GES-5 producing P. aeruginosa clinical isolates in medical settings in Japan, 1,476 carbapenem-resistant P. aeruginosa isolates obtained from 2012 to 2016 were characterized. Of these 1,476 isolates, 104 (7.0%) harbored blaGES-5. Southern blotting revealed that the blaGES-5 was located on the chromosome. The isolation rates of these GES-5 producers increased significantly every year, from 2.0% (6 of 295) in 2012 to 2.8% (8 of 283) in 2013 to 5.3% (16 of 303) in 2014 to 9.7% (29 of 300) in 2015 to 15.3% (45 of 295) in 2016. Of the 104 GES-5 producers, 102 belonged to clonal complex (CC) 235, including 99 belonging to ST235 and three belonging to ST2233). Whole genome sequence analysis revealed that CC235 P. aeruginosa harboring blaGES-5 spread in a clonal manner. These results indicate that these GES-5 producing CC235 P. aeruginosa clinical isolates have spread in medical settings throughout Japan.

show abstract

Section: Discussionmentioning

confidence: 99%

Spread of GES-5 carbapenemase-producing Pseudomonas aeruginosa clinical isolates in Japan due to clonal expansion of ST235

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Detection of carbapenemase-producing Acinetobacter with this method is more problematic, with 36.3% to 95.7% sensitivity and 28.6% to 100% specificity (155). Another study has shown mCIM to have low sensitivity (45.1%) for the detection of carbapenemases in Acinetobacter and Pseudomonas (174). A new method, termed CIMTris, has been developed to detect carbapenemases in Acinetobacter and Pseudomonas.…”

Section: Detection Of Carbapenemase Activitymentioning

confidence: 99%

“…A new method, termed CIMTris, has been developed to detect carbapenemases in Acinetobacter and Pseudomonas. The method is modified by extracting carbapenemases from bacteria with 0.5 M Tris hydrochloride and has 97.6% sensitivity and 92.6% specificity (174).…”

Section: Detection Of Carbapenemase Activitymentioning

confidence: 99%

NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings

et al. 2019

View full text Add to dashboard Cite

SUMMARYNew Delhi metallo-β-lactamase (NDM) is a metallo-β-lactamase able to hydrolyze almost all β-lactams. Twenty-four NDM variants have been identified in >60 species of 11 bacterial families, and several variants have enhanced carbapenemase activity.Klebsiella pneumoniaeandEscherichia coliare the predominant carriers ofblaNDM, with certain sequence types (STs) (forK. pneumoniae, ST11, ST14, ST15, or ST147; forE. coli, ST167, ST410, or ST617) being the most prevalent. NDM-positive strains have been identified worldwide, with the highest prevalence in the Indian subcontinent, the Middle East, and the Balkans. MostblaNDM-carrying plasmids belong to limited replicon types (IncX3, IncFII, or IncC). Commonly used phenotypic tests cannot specifically identify NDM. Lateral flow immunoassays specifically detect NDM, and molecular approaches remain the reference methods for detectingblaNDM. Polymyxins combined with other agents remain the mainstream options of antimicrobial treatment. Compounds able to inhibit NDM have been found, but none have been approved for clinical use. Outbreaks caused by NDM-positive strains have been reported worldwide, attributable to sources such as contaminated devices. Evidence-based guidelines on prevention and control of carbapenem-resistant Gram-negative bacteria are available, although none are specific for NDM-positive strains. NDM will remain a severe challenge in health care settings, and more studies on appropriate countermeasures are required.

show abstract

“…The mCIM is not currently recommended for the detection of carbapenemase activity in A. baumannii. A modification to the mCIM using 0.5 M Tris-HCl buffer for extraction (CIMTris) detected carbapenemase production in Acinetobacter and Pseudomonas species with a sensitivity of 98% and specificity of 93% (46).…”

Section: Overview Of Phenotypic Assaysmentioning

confidence: 99%

Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates

2018

View full text Add to dashboard Cite

The rapid spread of multidrug-resistant Gram-negative organisms constitutes one of the greatest challenges to global health. While Gram-negative organisms have developed several mechanisms to avert the bactericidal effects of commonly prescribed antibiotic agents, the increasing prevalence of carbapenemase-producing organisms (CPO) is particularly concerning given the rapid spread of mobile genetic elements containing carbapenemase genes, the limited treatment options for infections caused by these organisms, and the high mortality rates associated with CPO infections. Understanding if an organism is carbapenemase producing and, if so, the class of carbapenemase(s) produced has treatment implications, as some agents preferentially have activity against specific carbapenemases. Furthermore, CPO disseminate between patients with greater ease than non-CP-carbapenem-resistant organisms and warrant more intensive infection control measures than would be employed in the absence of carbapenemase production. Phenotypic assays currently used in clinical practice to detect CPO consist of the following: (i) growth-based assays which measure carbapenem resistance based on organism growth in the presence of a carbapenem antibiotic (e.g., modified Hodge test and modified carbapenem inactivation method), (ii) hydrolysis methods which detect carbapenem degradation products (e.g., Carba NP test and matrix-assisted laser desorption-ionization time of flight mass spectrometry), and (iii) lateral flow immunoassays which detect carbapenemase enzymes through the use of specific antibodies. Although there is no single phenotypic test that meets all specifications of the ideal test, as we describe in this review, there are a number of tests that are user-friendly, affordable, accurate, and feasible for implementation in clinical microbiology laboratories of all sizes.

show abstract

A Modified Carbapenem Inactivation Method, CIMTris, for Carbapenemase Production in Acinetobacter and Pseudomonas Species

Cited by 45 publications

References 16 publications

Spread of GES-5 carbapenemase-producing Pseudomonas aeruginosa clinical isolates in Japan due to clonal expansion of ST235

Spread of GES-5 carbapenemase-producing Pseudomonas aeruginosa clinical isolates in Japan due to clonal expansion of ST235

NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings

Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates

Contact Info

Product

Resources

About